Which corticosteroid formulation is used to limit systemic effects in mild-to-moderate ulcerative colitis?

Which corticosteroid formulation is used to limit systemic effects in mild-to-moderate ulcerative colitis?

• A. Budesonide (on a targeted colonic/ileal release formulation)
• B. Prednisone
• C. Hydrocortisone enema
• D. Dexamethasone

Answer: (A)

Targeted-release corticosteroids that deliver mainly to the inflamed bowel while being rapidly inactivated in the liver are used to limit systemic exposure. Budesonide with a colonic/ileal release formulation provides strong local anti-inflammatory effects in the colon, but because it undergoes extensive first-pass metabolism in the liver, only a small amount reaches systemic circulation. That combination—effective local action with minimal systemic glucocorticoid exposure—makes it the best choice for mild-to-moderate ulcerative colitis. Systemic steroids like prednisone or dexamethasone affect the whole body and carry more systemic side effects. Hydrocortisone enema targets distal disease and has less systemic exposure than oral steroids, but it may not adequately reach more proximal disease, whereas budesonide’s targeted release addresses a broader extent of colitis with fewer systemic effects.

Targeted-release corticosteroids that deliver mainly to the inflamed bowel while being rapidly inactivated in the liver are used to limit systemic exposure. Budesonide with a colonic/ileal release formulation provides strong local anti-inflammatory effects in the colon, but because it undergoes extensive first-pass metabolism in the liver, only a small amount reaches systemic circulation. That combination—effective local action with minimal systemic glucocorticoid exposure—makes it the best choice for mild-to-moderate ulcerative colitis.

Systemic steroids like prednisone or dexamethasone affect the whole body and carry more systemic side effects. Hydrocortisone enema targets distal disease and has less systemic exposure than oral steroids, but it may not adequately reach more proximal disease, whereas budesonide’s targeted release addresses a broader extent of colitis with fewer systemic effects.